CD274 and non-small cell lung carcinoma: In light of these evidences, the PD-L1 testing has been incorporated within the international guidelines and it is now recommended together with the molecular testing for all patients with newly diagnosed advanced NSCLC, in order to ensure the most effective upfront treatment for each patient [3].